Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: The present invention provides methods of assessing protein modification status and identifying biomarkers linked to cell signaling pathways. The invention provides a method of creating a dataset of modification sites, comprising grouping modification sites on modified peptides from a first sample which has been treated with a first modulator of a protein modifying enzyme and modification sites on modified peptides from a second sample which has been treated with a second modulator of the same protein modifying enzyme into a single group, according to the effect of said first and second modulators of said protein modifying enzyme on said modification sites, wherein said first and second modulators of said protein modifying enzyme are different. The invention further provides a method of preparing a database, methods of treatment and methods of diagnosis.

Abstract: The present invention provides a system comprising: (i) a layer containing a nitrite; and (ii) a hydrogel that contains hydrogen ions; wherein the layer containing a nitrite and/or the hydrogel comprises a pharmaceutically active agent. The invention also provides the use of a system of the invention in medicine, and in the treatment of pain.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: The present invention relates to the treatment of trauma haemorrhage or trauma haemorrhage-induced organ injury and associated disorders (in particular stoke, burns and brain injury) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the treatment of myocardial infarction and coronary heart disease (and associated disorders) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the use of artemisinin and its derivatives in coronary artery bypass surgery, heart transplantation, and diseases associated with ischaemia-reperfusion.

Abstract: The present invention provides the use of RNA removal to initiate protein aggregation of a plurality of proteins in a cell or cell lysate. This may be used to create an in vitro model of a disease, such as a neurodegenerative disease. The present invention also provides a method for determining the efficacy of a potential anti-protein aggregation agent comprising the following steps: i) using RNA removal to initiate the aggregation of a protein in a cell or cell lysate, ii) treating the cell or cell lysate with the potential anti-protein aggregation agent before, after or during RNA removal; and iii) comparing protein aggregation in equivalent samples with and without step ii) treatment in which a decrease in protein aggregation associated with step ii) treatment indicates that the potential anti-protein aggregation agent is effective in preventing and/or reversing protein aggregation.

Abstract: A method for determining the prognosis of prostate cancer in a subject is provided which comprises the assessment of the methylation status of the HSPB1 gene in a prostate cancer sample.

Abstract: A method for generating music is provided, the method comprising receiving, on a capacitive touch sensitive interface such as a keyboard, multi-finger gesture inputs having a first component and a second component, wherein the second component has a temporal evolution such as speed; determining the onset of an audio signal, such as a tone, based on the first component, analyzing the temporal evolution of the second component to determine MIDI or Open Sound Control OSC instructions; modifying the audio signal based on the instructions, in particular by decoupling the temporal relationship between specific gesture inputs (e.g. at key onset, during a note and upon key release), thus mapping gesture and motion inputs, to thus obtain previously unachievable musical effects with music synthesizers.

Abstract: The present invention provides a method for determining whether a Rheumatoid Arthritis (RA) patient is susceptible to treatment with a B cell targeted therapy, which method comprises the step of analysing B cells and/or germinal centre-like structures (GC-LS) in a synovial tissue sample from the patient; wherein a patient whose synovial tissue sample is B cell rich and/or GC-LS negative is determined to be susceptible to treatment with the B cell targeted therapy, whereas a patient whose synovial tissue sample is B-cell poor and/or GC-LS positive is determined to be resistant to treatment with the B cell targeted therapy.

Abstract: The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods.

Abstract: The present invention provides a system comprising: (i) a layer containing a nitrite; and (ii) a hydrogel that contains hydrogen ions. The invention also provides the use of a system of the invention for the treatment of a condition associated with tissue ischaemia or a wound and the use of a system of the invention in combination with an anaesthetic for the treatment or prevention of pain.

Abstract: The present invention relates to a method for manufacturing a three-dimensional (3D) biomimetic scaffold that exploits the use of electrical fields and electrical insulating materials to pattern previously polymerized hydro gels with different molecules and/or macromolecular entities. The invention also relates to the 3D-biomimetic scaffolds obtained and to the uses and applications thereof.

Abstract: The present invention relates to the treatment of trauma haemorrhage or trauma haemorrhage-induced organ injury and associated disorders (in particular stoke, burns and brain injury) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the treatment of myocardial infarction and coronary heart disease (and associated disorders) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the use of artemisinin and its derivatives in coronary artery bypass surgery, heart transplantation, and diseases associated with ischaemia-reperfusion.

Abstract: The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods.

Abstract: The present invention provides photocatalysts capable of catalytic activity in the visible range of light comprising platinum group metal nanoparticles deposited on a metal oxide support. The nanoparticles have surface plasmon resonance in the visible range of light. The invention also provides processes for preparing the photocatalysts, methods of liquid and gas purification using the photocatalysts of the invention and devices for the same.

Abstract: Mechanisms for obtaining an audio signal and information relating to the recording conditions of the audio signal are provided, the method comprising: obtaining an audio signal, wherein the audio signal is a voltage signal representation of sound, the voltage signal having been converted from a pressure signal; obtaining first information indicative of at least one objective feature and/or at least one perceptual feature associated with the conversion of the pressure signal into the audio signal in the form of a voltage signal representation; storing the audio signal, the first information, and second information identifying a relationship between the audio signal and the first information; determining an error adjustment for adjusting the audio signal based on the obtained information; applying the error adjustment to the audio signal to create an error-adjusted audio signal; and obtaining an audio signal and information relating to the recording conditions of the audio signal.

Abstract: The present invention provides dental compositions and devices comprising a rechargeable fluoride delivery system wherein the rechargeable fluoride delivery system comprises a layered double hydroxide with the formula M(II)1?x M(III)x (OH)2 (An?)x/n yH2O where M(II) is a divalent cation, M(III) is a trivalent cation, A is an anion with a charge, x is a value between 0.2 and 0.33, y is an integer between 1 and 10 and n has a value of 1.

Abstract: There is provided a method for replicating HCV virus in vitro which comprises the following steps: (i) fusing an HCV-infected white blood cell with a hepatocyte cell to produce a fused cell; and (ii) culturing the fused cell so that HCV replication may occur. There is also provided a fused cell capable of replicating HCV virus in vitro which is made by fusing an HCV-infected white blood cell with a hepatocyte cell, and uses of such a fused cell to screen for anti-HCV drugs and assessing patient responsiveness to therapy before treatment.

Abstract: The present invention provides a method of quantifying the activity of a protein modifying enzyme in a sample, comprising: (i) grouping modified peptides from a first sample and modified peptides from a second sample into a single group according to one of the following parameters: (a) modified peptides having a modification site that is modified by the same protein modifying enzyme; or (b) modified peptides having a modification site that is part of the same modification motif; (ii) calculating enrichment of the modified peptides from the first sample compared to the modified peptides from the second sample in the group; and (iii) calculating the statistical significance of said enrichment; wherein a statistically significant enrichment is indicative of a protein modifying enzyme being activated in the first sample compared to the second sample. In some embodiments, the method further comprises identifying modified peptides in a first sample and a second sample using mass spectrometry (MS) prior to step (i).